Latest Data


« Subject Safety And Efficacy Of Sunitinib In An Expanded-access Trial Of Metastatic Renal Cell Carcinoma (mrcc) | Main | Comments Requested Controversial Anemia Drug Doesn’t Cut Need For Transfusions (healthday) »

Subject Gsk Receives Positive Opinion For Conditional Approval Of New Oral Breast Cancer Treatment, Tyverb (lapatinib)

By admin2 | May 31, 2008

MedicalGlaxoSmithKline (GSK) announced that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a revised positive opinion confirming the positive benefit-risk profile for Tyverb® (lapatinib), GSK’s new oral treatment for breast cancer. The positive opinion recommends grant of a conditional marketing authorisation.The CHMP previously issued a positive opinion for lapatinib in December 2007.
(Link)

This entry was important to me: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • StumbleUpon
  • Digg
  • del.icio.us
  • Reddit
  • Furl
  • Junipo

Topics: Cancer |

Comments